Evidence map›Paper›PMID 28285599›Full record

ArticleMicrobiome2017

Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E

Paul M Ryan, Lis E E London, Trent C Bjorndahl, Rupasri Mandal, Kiera Murphy, Gerald F Fitzgerald, Fergus Shanahan, R Paul Ross, David S Wishart, Noel M Caplice and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiome, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Live Metabolomics with NMR.Analytical chemistry · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. β-1,6-Glucan FromFrontiers in immunology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Paul M RyanDepartment of Food Biosciences, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.
Lis E E LondonDepartment of Food Biosciences, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.
Trent C BjorndahlDepartment of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
Rupasri MandalDepartment of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
Kiera MurphyDepartment of Food Biosciences, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.
Gerald F FitzgeraldSchool of Microbiology, University College Cork, Co. Cork, Ireland.
Fergus ShanahanDepartment of Medicine, University College Cork, National University of Ireland, Cork, Ireland.
R Paul RossAPC Microbiome Institute, Biosciences Institute, University College Cork, Co. Cork, Ireland.
David S WishartDepartment of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
Noel M CapliceCentre for Research in Vascular Biology, University College Cork, Co. Cork, Ireland.
Catherine StantonDepartment of Food Biosciences, Teagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland. Catherine.Stanton@teagasc.ie.
APC Microbiome Institute · IETeagasc - The Irish Agriculture and Food Development Authority · IEUniversity of Alberta · CAUniversity College Cork · IE

Funding

HEPATITIS C VIRAL MUTANTS AND HUMAN T CELL FUNCTIONK01DK002970 · NIDDK · UNIVERSITY OF ILLINOIS AT CHICAGO · PI WANG, HUIRU · 2001 to 2003
$265k
NIDDK NIH HHS K01 DK002970
6 · The paper itself

Abstract

backgroundThere is strong evidence indicating that gut microbiota have the potential to modify, or be modified by the drugs and nutritional interventions that we rely upon. This study aims to characterize the compositional and functional effects of several nutritional, neutraceutical, and pharmaceutical cardiovascular disease interventions on the gut microbiome, through metagenomic and metabolomic approaches. Apolipoprotein-E-deficient mice were fed for 24 weeks either high-fat/cholesterol diet alone (control, HFC) or high-fat/cholesterol in conjunction with one of three dietary interventions, as follows: plant sterol ester (PSE), oat β-glucan (OBG) and bile salt hydrolase-active Lactobacillus reuteri APC 2587 (BSH), or the drug atorvastatin (STAT). The gut microbiome composition was then investigated, in addition to the host fecal and serum metabolome.

resultsWe observed major shifts in the composition of the gut microbiome of PSE mice, while OBG and BSH mice displayed more modest fluctuations, and STAT showed relatively few alterations. Interestingly, these compositional effects imparted by PSE were coupled with an increase in acetate and reduction in isovalerate (p < 0.05), while OBG promoted n-butyrate synthesis (p < 0.01). In addition, PSE significantly dampened the microbial production of the proatherogenic precursor compound, trimethylamine (p < 0.05), attenuated cholesterol accumulation, and nearly abolished atherogenesis in the model (p < 0.05). However, PSE supplementation produced the heaviest mice with the greatest degree of adiposity (p < 0.05). Finally, PSE, OBG, and STAT all appeared to have considerable impact on the host serum metabolome, including alterations in several acylcarnitines previously associated with a state of metabolic dysfunction (p < 0.05).

conclusionsWe observed functional alterations in microbial and host-derived metabolites, which may have important implications for systemic metabolic health, suggesting that cardiovascular disease interventions may have a significant impact on the microbiome composition and functionality. This study indicates that the gut microbiome-modifying effects of novel therapeutics should be considered, in addition to the direct host effects.

Indexed as

Gastrointestinal MicrobiomeMetabolomeAcetatesAnimalsApolipoproteins EAtherosclerosisAtorvastatinbeta-GlucansButyratesCardiovascular DiseasesCarnitineCholesterolCholesterol, DietaryDietary SupplementsDiet, High-FatFecesAcetatesacylcarnitineApolipoproteins EAtorvastatinbeta-glucan, (1-3)(1-4)-beta-GlucansButyratesCarnitineCholesterolCholesterol, DietaryHemiterpenesisovaleric acidPentanoic AcidsApo-E-deficientAtherosclerosisCardiovascular diseaseMetabolomeMicrobiome

Identifiers

PMID28285599
PMCPMC5346842
OpenAlexW2592521458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.